IFNA2 and Hepatic fibrosis: These data suggest that resolution of inflammation in the liver associated with chronic HCV infection is much more rapid in patients treated with DAA therapy than in patients treated with IFNα/ribavirin and this may be ultimately reflected in regression of liver fibrosis following HCV cure.